A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

201489 citationsJournal Articlehybrid Open Access

Authors

Irene Braña · Princess Margaret Cancer Centre

Raanan Berger · Sheba Medical Center

Talia Golan · Sheba Medical Center

Paul Haluska · Mayo Clinic in Arizona

Jeff Edenfield · Prisma Health

J. Fiorica · Sarasota Memorial Hospital

John Stephenson ·

Abstract

Dalotuzumab/MK-2206 and dalotuzumab/MK-0752 combinations were tolerable. Further developments of prospectively validated predictive biomarkers to aid in patient selection for anti-IGF-1R therapies are needed.

Topics & Keywords

Growth Hormone and Insulin-like Growth Factors PI3K/AKT/mTOR signaling in cancer Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 111, Issue 10, pp. 1932-1944

DOI: 10.1038/bjc.2014.497

Field-Weighted Citation Impact: 8.15